Diabetesapp tar in 300 miljoner i finansieringsrunda
Den svensk-amerikanska diabetsappen Glooko har tagit in 300 miljoner kronor i en finansieringsrunda, rapporterar DI Digital. Pengarna ska gå till att bredda sig i Europa, säger expanderingsansvarige Anders Sonnesson till tidningen.
– USA har varit vår största marknad men vi hoppas att vi kan satsa mer i framför allt Tyskland och Frankrike.
Investerare är bland annat Samsung Ventures och riskkapitalbolaget Georgian Partners, skriver tidningen.
bakgrund
Glooko
Wikipedia (en)
Glooko, Inc provides a Software-as-a-Service (SaaS) application and accompanying mobile app for diabetes patients and their healthcare providers in the United States and internationally.
An mHealth, Telemedicine and Population Management offering, Glooko is an FDA 510(k) cleared, HIPPA compliant unified diabetes management platform that is used by both patients and their Health Care Providers (HCP). Accountable Care Organizations and Integrated Health Systems seeking to remotely monitor patient health to improve patient outcomes and reduce the costs of delivery, hospitalizations and emergency room visits have started to use telemedicine applications for patient remote monitoring to enable early warning and proactive action for issues related to chronic diseases like diabetes and hypertension.
Glooko consists of a patient mobile app, a provider population management app accessed online and a meter sync hardware device which delivers insights and population management features and enables patients to upload data from their blood glucose meters. Glooko currently supports syncing data from more than 30 blood glucose meters using a proprietary meter sync cable called the MeterSync Blue, and patients can check their blood glucose meter for compatibility on the website.
Glooko also automatically pulls in data from popular fitness trackers and biometric devices. Pumps and CGMs are slated to be added to Glooko in the summer of 2015.
Omni är politiskt obundna och oberoende. Vi strävar efter att ge fler perspektiv på nyheterna. Har du frågor eller synpunkter kring vår rapportering? Kontakta redaktionen